232 related articles for article (PubMed ID: 22108341)
41. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
[TBL] [Abstract][Full Text] [Related]
42. Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer.
Kohno N; Kitahara S; Tamura E; Tanabe T
Oncology; 2002; 63(3):226-31. PubMed ID: 12381901
[TBL] [Abstract][Full Text] [Related]
43. A comparative study of low dose weekly paclitaxel versus cisplatin with concurrent radiation in the treatment of locally advanced head and neck cancers.
Jain RK; Kirar P; Gupta G; Dubey S; Gupta SK; Goyal J
Indian J Cancer; 2009; 46(1):50-3. PubMed ID: 19282567
[TBL] [Abstract][Full Text] [Related]
44. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY
Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506
[TBL] [Abstract][Full Text] [Related]
45. Induction chemotherapy with carboplatin-paclitaxel followed by standard radiotherapy with concurrent daily low-dose cisplatin plus weekly paclitaxel for inoperable non-small-cell lung cancer.
Ardizzoni A; Scolaro T; Mereu C; Cafferata MA; Tixi L; Bacigalupo A; Tiseo M; Monetti F; Rosso R
Am J Clin Oncol; 2005 Feb; 28(1):58-64. PubMed ID: 15685036
[TBL] [Abstract][Full Text] [Related]
46. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
[TBL] [Abstract][Full Text] [Related]
47. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
48. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
49. Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Franco P; Potenza I; Schena M; Riva G; Pecorari G; Garzino Demo P; Fasolis M; Moretto F; Garzaro M; Di Muzio J; Melano M; Airoldi M; Ragona R; Rampino M; Ricardi U
Anticancer Res; 2015 Nov; 35(11):6247-54. PubMed ID: 26504058
[TBL] [Abstract][Full Text] [Related]
50. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
[TBL] [Abstract][Full Text] [Related]
51. Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy.
Hancock SB; Krempl GA; Canfield V; Bogardus C; Kojouri K; Kaneaster SK; Medina JE
Laryngoscope; 2008 Aug; 118(8):1357-61. PubMed ID: 18528311
[TBL] [Abstract][Full Text] [Related]
52. Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results.
Chougule P; Wanebo H; Akerley W; McRae R; Nigri P; Leone L; Safran H; Ready N; Koness RJ; Radie-Keane K; Cole B
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-57-S19-61. PubMed ID: 9427268
[TBL] [Abstract][Full Text] [Related]
53. Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin.
Gómez-Millán J; Toledo MD; Lupiañez Y; Rueda A; Trigo JM; Sachetti A; Medina JA
Clin Transl Oncol; 2013 Apr; 15(4):321-6. PubMed ID: 22911552
[TBL] [Abstract][Full Text] [Related]
54. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
[TBL] [Abstract][Full Text] [Related]
55. [Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Chilimoniuk M; Olszewska E; Maksimowicz T
Pol Merkur Lekarski; 2010 Dec; 29(174):357-60. PubMed ID: 21298984
[TBL] [Abstract][Full Text] [Related]
56. Feasibility and tolerance of sequential chemoradiotherapy in squamous cell carcinoma of the head and neck.
Loo SW; Geropantas K; Tasigiannopoulos Z; Martin C; Roques TW
Eur J Cancer Care (Engl); 2013 Jan; 22(1):32-40. PubMed ID: 22519981
[TBL] [Abstract][Full Text] [Related]
57. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
Hitt R; Jimeno A; Millán JM; Castellano D; Cortés-Funes H
Cancer; 2004 Aug; 101(4):768-75. PubMed ID: 15305408
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of concomitant chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced squamous cell head and neck cancers.
Baykara M; Buyukberber S; Ozturk B; Coskun U; Unsal DK; Demirci U; Dane F; Kaplan MA; Bora H; Benekli M
Asian Pac J Cancer Prev; 2013; 14(4):2557-61. PubMed ID: 23725174
[TBL] [Abstract][Full Text] [Related]
59. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
Swisher SG; Winter KA; Komaki RU; Ajani JA; Wu TT; Hofstetter WL; Konski AA; Willett CG
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1967-72. PubMed ID: 21507583
[TBL] [Abstract][Full Text] [Related]
60. Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study.
Fountzilas G; Tolis C; Kalogera-Fountzila A; Misailidou D; Tsekeris P; Karina M; Nikolaou A; Samantas E; Makatsoris T; Athanassiou E; Skarlos D; Bamias A; Zamboglou N; Economopoulos T; Karanastassi S; Pavlidis N; Daniilidis J
Med Oncol; 2005; 22(3):269-79. PubMed ID: 16110138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]